Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-12-20
2005-12-20
Padmanabhan, Sreenivasan (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S212010
Reexamination Certificate
active
06977253
ABSTRACT:
Carbamazepine, in extended release form, is useful in the treatment of patients suffering from bipolar disorder. In order to minimize the time it takes to reach efficacy, carbamazepine, in extended release form, can be administered to the patient at an initial daily dose which is then increased in daily increments until clinical efficacy is achieved.
REFERENCES:
patent: 2948718 (1960-08-01), Schindler et al.
patent: 5326570 (1994-07-01), Rudnic et al.
patent: 5912013 (1999-06-01), Rudnic et al.
patent: 0 029 409 (1981-05-01), None
patent: 0 277 095 (1988-08-01), None
patent: 0 423 679 (1991-04-01), None
patent: 0 485 685 (1992-05-01), None
patent: 0 688 768 (1995-12-01), None
Simhandl et al. The comparative efficacy of carbamazepine low and igh serum level and lithium carbonate in the propylaxis of affective disorders. Journal of Affective Disorders, 28 (1993) pp. 221-231.
The use of carbamazepine (Tegretol) in the control of manic-depressive psychosis and other manic, depressive states, Takezaki H and Hanaoka M.Clinical Psychiatry1971; 13: 173-183.
“Anti-Manic and Prophylactic Effects of Carbamazepine (Tegretol) on Manic Depressive Psychosis”, Teruo Okuma et al., Folia Psychiatrica et Neurologica Japonica, vol. 27, No. 4, (1973).
“Comparison of the Antimanic Efficacy of Carbamazepine and Chlorpromazine: A Double-Blind Controlled Study”, Teruo Okuma et al., Psychopharmacology 66, 211-217 (1979).
Carbamazepine vs Chlorpromazepine in Mania: A Double Blind Trial, 1984 Elsevier Science Publishers B.V., Anticonvulsants in affective disorders, E. Grossi et al.
Carbamazepine Versus Lithium in Mania: A Double-Blind Study, Bernard Lerer et al., J. Clin. Psychiatry 48:3, Mar. 1987.
“Comparison of the Antimanic Efficacy of Carbamazepine and Lithium Carbonate by Double-Blind Controlled Study”, T. Okuma et al., Pharmacopsychiatry 23 (1990) 143-150.
“NCDEU Updates”, “Anticonvulsants in affective Disorders”, Joyce G. Small, Psychopharmacology Bulletin, vol. 26, No. 1, 25-36, 1990.
“Carbamazepine Compared With Lithium in the Treatment of Mania”, Joyce G. Small et al., Arch Gen Psychiatry—vol. 48, Oct. 1991.
“Carbamazepine and its 10,11-epoxide metabolite in acute mania: clinicaland pharmacokinetic correlates”, P. Petit et al., Eur. J. Clin. Pharmacol (1991) 41:541-546.
“Carbamazepine Expoxide” Bradley M. Kerr and René H. Levy, Antiepileptic Drugs, Fourth Edition, edited by R.H. Levy, R.H. Mattson and B.S. Meldrum, Raven Press Ltd 1995, 529-541.
“Carbamazepine Chemistry and Biotransformation”, Johann W. Faigle and Karl F. Feldmann, Antiepileptic Drugs, Fourth Edition, edited by R.H. Levy, R.H. Mattson and B.S. Meldrum, Raven Press, Ltd. New York 1995, 499-513.
“Dosing Strategies and Time Course of Response to Antimanic Drugs”, Charles L. Bowden, J. Clin. Psychiatry 1996;57 (suppl 13).
“Corrections”, in the Article “Rapid Titration of Mood Stabilizers Predicts Remission From Mixed or Pure Mania in Bipolar Patients”, Joseph F. Goldberg et al.,J. Clin. Psychiatry1998; 59:6, 320.
“Rapid Titration of Mood Stabilizers Predicts Remission From Mixed or Pure Mania in Bipolar Patients”, Joseph F. Goldberg et al.,J. Clin. Psychiatry59:4, Apr. 1998, 151-158.
“Pharmacokinetic Evaluation of Twice-Daily Extended-Release Carbamazepine (CBZ) and Four-Times-Daily Immediate-Release CBZ in Patients with Epilepsy”, William R. Garnett et al.,Epilepsia, 39(3):274-279, 1998.
“Controlled Multidose, Pharmacokinetic Evaluation of Two Extended-Release Carbamazepine Formulations (Carbatrol and Tegretol-XR)”, Ruth E. Stevens et al.Journal of Pharmaceutical Sciences, vol. 87, No. 12, Dec. 1998.
“Six-month evaluation of Carbatrol (extended-release carbamazepine) in complex partial seizures”, W.U. Mirza et al.Neurology, 19; 1727-1729, 1998.
“Anticonvulsants and Antipsychotics in the Tratment of Bipolar Disorder”, Paul E. Keck et al., . Clin, Psychiatry 1998;59 (suppl 6).
“New formulations of drugs in epilepsy”, James W. Wheless et al.,Exp. Opin, Pharmacother. (1999) 1(1):49-60.
“Gastrointestinal performance of the Microtrol extended release drug delivery technology”, P H Hirst et al., Proceed. Int'l Symp. Control. Rel. Bioact. Mater., 26(Revised Jul. 1999) Controlled Release Society, Inc.
“Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder”, Kamini Vasudev et al., Psychopharmacology (2000) 150:15-23.
“Extended Release Formulations of Anticonvulsant Medications”, Rebeccah J. Collins et al.,CNS Drugs2000 Sep. 14(3):203-212.
“The Influence of Food on the Bioavailability of a Twice-Daily Controlled Release Carbamazepine Formulation”, Angus McLean et al.J. Clin. Pharmacol. 2001 ; 41:183-186.
“Extended Release Carbamazepine: Optimizing Epilepsy Treatment”, Carbatrol “Extended Release Carbamazepine Capsules” Scientific Exhibit, Dec. 9, 2002, 2002 American Epilepsy Society Annual Meeting, Room 615.
“Open-Label, 6-Mont h Evaluation of the Safety and Efficacy of Extended-Release Carbamazepine Capsules (Carbatrol®) in Patients with Manic or Mixed Bipolar Disorder”, Terence A. Ketter et al., poster Dec. 9, 2002, 2002 American Epilepsy Society Annual Meeting.
“Reanalysis of Carbamazepine and Carbamazepine-Epoxide Pharmacokinetics after Multiple Dosing of Extended Release Formulations”, David H. Mason et al.,J. Pharm. Parmaceut Sci. 5(2):169-175, 2002.
“Administration of Carbatrol to Children With Feeding Tubes”, Jennifer R. Riss et al., Elsevier Science 2002.
“Open-Label, 6-Month Evaluation of the Safety and Efficacy of Extended-Release Carbamazepine Capsules (Carbatrol®) in Patients with Manic or Mixed Bipolar Disorder”, Terence A. Ketter, poster presented Dec. 9, 2002, at American Epilepsy Society 56th Annual Meeting, Dec. 6-11, 2002, Seattle, Washington.
“A Multicenter, Ramdomized, Double-Blind, Placebo-Controlled Trial of Extended-Release Carbamazepine Capsules (Carbatrol®) Monotherapy in Patients with Mania or Mixed Bipolar Disorders,” by R.H. Weisler, poster presented Dec. 9, 2002 at American Epilepsy Society 56th Annual Meeting, Dec. 6-11, 2002, Seattle, Washington.
“Extended-Release Carbamazepine (Carbatrol®) in Bipolar Disorders: A 6 Month Open-Trial,” by Mark B. Hamner and Terrence, A. Ketter, poster presented at APA 2003 American Psychiatric Association 156th Annual Meeting, May 17-22, 2003, San Francisco, California (Abstract NR491. p. 184).
“A 3-Week, Double-Blind, Placebo-Controlled Study of Extended-Release Carbamazepine in the Treatment of Acute Mania in Bipolar Disorders,” by A. H. Kalali, T. A. Ketter, and R. H. Weisler, poster presented at NCDEU 2003 43rd Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, May 26-28, 2003, Boca Raton, FL.
“Extended-Release Carbamazepine in Bipolar Disorders,” by T. A. Ketter, R. H. Weisler, and A. H. Kalali, poster presented at ICBD 2003 Fifth International Conference on Bipolar Disorder, Jun. 12-14, 2003, Pittsburgh, Pennsylvania.
“Open-Label, 6-Month Evaluation of the Safety and Efficacy of SPD-417 (Beaded, ERC-CBZ) in Patients with Manic or Mixed Bipolar Disorder”, Terence A. Ketter and Sherry L. Andes, poster presented at the meeting of American College of Clinical Pharmacy, Atlanta, Nov. 2-5, 2003.
“A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of SPD-417 (Beaded, ERC-Carbamazepine) Monotherapy in Patients with Mania or Mixed Bipolar Disorders,” R. H. Weisler and Sherry L. Andes, poster presented at the meeting of American College of Clinical Pharmacy, Atlanta, Nov. 2-5, 2003.
“Extended-Release Carbamazepine (Carbatrol©) in Bipolar Disorders: A 6 Month Open-Trial,
Kalali Amir H.
Tulloch Simon J.
Kim Jennifer
Millen White Zelano & Branigan P.C.
Padmanabhan Sreenivasan
Shire Pharmaceutical Development Inc.
LandOfFree
Methods for the treatment of bipolar disorder using... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of bipolar disorder using..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of bipolar disorder using... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3497273